Movers and SHAKERS
REQORSA Manufacturing is Scaled Up for Clinical Testing
Genprex Inc is a U.S.-based clinical-stage gene therapy company. It is engaged in developing a new approach to treating cancer based on its novel proprietary technology platform, including initial product candidate, Oncoprex immunogene therapy. Oncoprex, which has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis in cancer cells and modulates the immune response against cancer cells.
Ahu Demir, Ph. D., Senior Research Analyst, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
REQORSA is getting ready to be tested in the clinic. Today, Genprex (GNPX) announced the achievement of the clinical-grade production to supply the upcoming trials, Acclaim-1, and Acclaim-2 clinical trials. This is a major milestone for the company as manufacturing can represent a bottleneck in gene therapy. The shares gained over 18% upon the announcement (12:10 EST).
NSCLC market is large, and the combination strategy is solid. Acclaim-1 and Acclaim-2 clinical trials are set to assess REQORSA in combination with Tagrisso and with Keytruda, respectively for the treatment of...
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.